Show simple item record

dc.contributor.authorMarcuello, Maria
dc.contributor.authorDuran Sanchon, Saray
dc.contributor.authorMoreno, Lorena
dc.contributor.authorLozano, Juan José
dc.contributor.authorBujanda Fernández de Pierola, Luis ORCID
dc.contributor.authorCastells, Antoni
dc.contributor.authorGironella, Meritxell
dc.date.accessioned2019-12-12T08:40:56Z
dc.date.available2019-12-12T08:40:56Z
dc.date.issued2019-10-12
dc.identifier.citationCancers 11(10) : (2019) // Article ID 1542es_ES
dc.identifier.issn2072-6694
dc.identifier.urihttp://hdl.handle.net/10810/36805
dc.description.abstractEarly detection of colorectal cancer (CRC) and its precancerous lesion, advanced adenomas (AA), is critical to improve CRC incidence and prognosis. Circulating microRNAs (miRNAs or miR) are promising non-invasive biomarkers for cancer detection. Our previous results showed that a plasma 6-miRNA signature (miR-15b-5p, miR-18a-5p, miR-29a-3p, miR-335-5p, miR-19a-3p and miR-19b-3p) could distinguish between CRC or AA and healthy individuals (controls). However, its diagnostic performance in serum is unknown. In this exploratory study we aim to evaluate the diagnostic performance of the 6-miRNA signature in serum samples in a cohort of individuals participating in Barcelona's CRC Screening Programme. We prospectively collected serums from 264 faecal immunochemical test (FIT)-positive participants and total RNA was extracted. Finally, 213 individuals (CRC, 59, AA, 74, controls, 80) were included. MiRNA expression was quantified by real-time RT-qPCR and data analysis was performed by logistic regression. Faecal hemoglobin concentration (f(Hb)) from FIT of the same individuals was also considered. As previously described in plasma, serum from patients with AA or CRC presented significant differences in the 6-miRNA signature compared to controls. Moreover, when combined with f(Hb), the final signature showed high discriminative capacity to distinguish CRC from controls (area under the curve (AUC) = 0.88), and even AA (AUC = 0.81) that otherwise are poorly detected if we only consider f(Hb) (AUC = 0.64). Addition of the serum 6-miRNA signature to quantitative f(Hb) show high accuracy to detect patients with advanced colorectal neoplasia in average-risk individuals. A combination of these two non-invasive methods could be a good strategy to improve diagnostic performances of current CRC screening programmes.es_ES
dc.description.sponsorshipThe present work was supported by Fundacion Cientifica de la Asociacion Espanola contra el Cancer (GCB13131592CAST), Instituto de Salud Carlos III (PI17/01003), Ministerio de economia y competitividad (RTC-2015-3850-1, SAF2014-54453-R) and co-funded by FEDER-European Union. CIBEREHD is funded by the Instituto de Salud Carlos III. We also acknowledge the support of the CERCA Programme and SGR 653 from Generalitat de Catalunya. This work was developed at the Centro Esther Koplowitz, Barcelona, Spain.es_ES
dc.language.isoenges_ES
dc.publisherMDPIes_ES
dc.relationinfo:eu-repo/grantAgreement/MINECO/RTC-2015-3850-1es_ES
dc.relationinfo:eu-repo/grantAgreement/MINECO/SAF2014-54453-Res_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.subjectcolorectal canceres_ES
dc.subjectscreeninges_ES
dc.subjectnon-invasive biomarkeres_ES
dc.subjectearly detectiones_ES
dc.subjectadvanced adenomaes_ES
dc.subjectcirculating mirnaes_ES
dc.subjectserumes_ES
dc.subjectliquid biopsyes_ES
dc.subjectcirculating micrornases_ES
dc.subjectpotential biomarkerses_ES
dc.subjectproximal colones_ES
dc.subjectplasmaes_ES
dc.subjectmarkerses_ES
dc.titleAnalysis of A 6-Mirna Signature in Serum from Colorectal Cancer Screening Participants as Non-Invasive Biomarkers for Advanced Adenoma and Colorectal Cancer Detectiones_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.holder©2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open accessarticle distributed under the terms and conditions of the Creative Commons Attribution(CC BY) license (http://creativecommons.org/licenses/by/4.0/)es_ES
dc.rights.holderAtribución 3.0 España*
dc.relation.publisherversionhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6827108/es_ES
dc.identifier.doi10.3390/cancers11101542
dc.contributor.funderEuropean Commission
dc.departamentoesMedicinaes_ES
dc.departamentoeuMedikuntzaes_ES


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

©2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open accessarticle distributed under the terms and conditions of the Creative Commons Attribution(CC BY) license (http://creativecommons.org/licenses/by/4.0/)
Except where otherwise noted, this item's license is described as ©2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open accessarticle distributed under the terms and conditions of the Creative Commons Attribution(CC BY) license (http://creativecommons.org/licenses/by/4.0/)